Pure Global: Brazil's AI Software Maze - Cracking ANVISA's New Code

In this episode, we dissect the breaking news from Brazil where the regulatory agency, ANVISA, has just rolled out a comprehensive and stricter framework for AI-powered Software as a Medical Device (SaMD). This sudden move creates significant new barriers to entry in Latin America's most lucrative MedTech market. We explore the immediate and costly implications for international manufacturers, whose existing global dossiers and market-entry strategies may now be insufficient. We use the real-world example of a company poised to launch its innovative diagnostic software, only to be stopped in its tracks by a new, unexpected demand for local clinical data and cybersecurity compliance, forcing a difficult decision between a costly new trial or abandoning the market. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD regulation? - Why is Brazil now demanding local clinical data for AI algorithm validation? - How does this new framework impact your existing device classification and submission strategy? - What specific cybersecurity protocols are now mandatory for market access? - Can your existing technical file from the US or EU be leveraged, or must you start from scratch? - What are the hidden costs and timelines associated with this new regulation? - How can you turn this regulatory hurdle into a long-term competitive advantage in the LATAM region? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline global market access. We act as your local representative in Brazil and over 30 other markets, developing efficient pathways for regulatory approval. Turn regulatory complexity into a strategic advantage. Contact us at [email protected] or visit https://pureglobal.com/.